

Special Issue

Diagnosis, Pathogenesis and Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Message from the Guest Editor

This Special Issue will focus on emerging trends in the diagnosis, monitoring and treatment of chronic obstructive pulmonary disease (COPD). Although progress has been demonstrated in its treatment, there is still room for substantial improvement regarding a wide range of topics within COPD. Relevant biomarkers or other ways of measuring disease status are lacking for COPD. New treatment options for COPD have not been introduced for more than a decade. Therefore, the discovery and introduction of new mechanisms with the potential to develop therapeutic strategies is needed, as are diagnostic, prognostic and predictive biomarkers. This Special Issue invites the submission of research in any area relating to these themes include (not limited to) the following:

- Identification of novel biomarkers
- Phenotyping
- Treatment
- Prognosis
- Disease monitoring
- Early diagnosing
- Molecular mechanisms
- Strategies to improve management
- Evaluation of new biomarkers with predictive value

Guest Editor

Dr. Anders Løkke

1. Department of Medicine, Little Belt Hospital, Vejle, Denmark
2. Department of Regional Health Research, University of Southern Denmark, Odense, Denmark

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/159432

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).